Metastatic castration-resistant Prostate Cancer Patients with Homologous Recombination Repair Gene Alterations after Docetaxel Treatment
Pioneering new approaches in the treatment of metastatic castration-resistant prostate cancer!
Revive Research Institute is invested in introducing cutting-edge technology and life-changing clinical trials to advance medicine and healthcare. On our quest to breakthrough medicine, we have over 20 oncology studies being conducted on our sites, with more in the pipeline. We believe in driving the change to how we treat and diagnose cancer patients.
The American Cancer Society estimates that up to 191,930 men in the US were diagnosed with prostate cancer and approximately 33,330 will die of the disease in 2020. There is a dire need to find a novel treatment for prostate cancers for men all over the world.
In our quest to bring innovation in oncology, Revive Research Institute is working tirelessly towards new treatment options. We are conducting a clinical trial to find a combination of treatment options for Prostate Cancer patients.
Join us in research trials and be a part of the change!
- Be 18 years of age or older.
- Histologically or cytologically confirmed Prostate Adenocarcinoma.
- Comply with study procedures.
- Additional Criteria may apply.